Lahore: Citi Pharma Limited held its Annual General Meeting (AGM) on October 27, 2025, where shareholders unanimously passed a series of resolutions addressing both ordinary business matters and strategic decisions for the company’s future. The meeting took place at the company’s office in Johar Town.
The AGM began with the confirmation and adoption of the minutes from the last Extraordinary General Meeting held on June 26, 2025. Following this, shareholders reviewed and approved the Audited Financial Statements for the fiscal year ending June 30, 2025. These financial statements, audited by M/s. Aslam Malik & Co., Chartered Accountants, provide a comprehensive overview of the company’s financial health and performance over the past year.
According to information available from the Pakistan Stock Exchange (PSX), the appointment of M/s. Aslam Malik & Co. as the external auditors for the next fiscal year, ending June 30, 2026, was also confirmed. The decision was made by the Board of Directors and recommended by the Audit Committee, ensuring continuity in the auditing process.
A significant resolution passed during the meeting was the approval of a final cash dividend of Rs. 3.5 per share, representing 35% for the year ended June 30, 2025. This decision reflects the company’s commitment to delivering consistent returns to its shareholders.
The election of seven directors for a term of three years was another key agenda item. The board confirmed the election of the following directors: Mr. Nadeem Amjad, Mr. Rizwan Ahmad, Mr. Zameer Ul Hassan Shah, Mr. Muhammad Naeem, Mr. Abdul Jaleel Sheikh, Mrs. Saima Shafi Rana, and Mrs. Saira Aslam. These directors will lead the company in accordance with the provisions of the Companies Act, 2017, replacing the outgoing board members.
The AGM concluded without any additional business, with a formal vote of thanks extended to the Chair, marking a successful and decisive meeting in the company’s calendar.